A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT ID: NCT06755242

Last Updated: 2025-01-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-31
• Study Completion Date: 2027-12-31

Brief Summary

This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.

Conditions

Gastrointestinal Tumors; Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GNC-077

Participants receive GNC-077 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

GNC-077

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Interventions

GNC-077

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;

2. Gender is not limited;

3. Age: ≥18 years old and ≤75 years old (phase Ia); ≥18 years old (phase Ib);

4. Patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors confirmed by histopathology and/or cytology who failed standard treatment;

5. Must have at least one measurable lesion that meets the RECIST v1.1 definition;

6. Have archived primary or recurrent tumor tissue specimens that can be submitted for central review;

7. ECOG ≤1;

8. The expected survival time as judged by the investigators was ≥3 months;

9. Bone marrow function, renal function and liver function need to meet the requirements;

10. Coagulation function: fibrinogen ≥1.5 g/L; Activated partial thromboplastin time (APTT) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN;

11. Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 12 weeks after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose;

12. Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion Criteria

1. Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;

2. Patients with active infection requiring intravenous antibiotics that had not been completed more than 1 week before enrollment, with the exception of prophylactic antibiotics for puncture or biopsy;

3. Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;

4. Toxicity from prior antineoplastic therapy is not reduced to grade I as defined in CTCAE, version 5.0;

5. Patients at risk for active autoimmune disease or with a history of autoimmune disease may have central nervous system involvement;

6. Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis;

7. Patients with previous allogeneic hematopoietic stem cell transplantation or organ transplantation;

8. Had a history of severe cardiovascular and cerebrovascular diseases;

9. Patients with or with unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism within 6 months before screening;

10. Brain parenchymal metastases and/or meningeal metastases or spinal cord compression, excluding stable and asymptomatic brain parenchymal metastases;

11. Patients with massive or symptomatic effusions or poorly controlled effusions;

12. Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large arteries;

13. Subjects with clinically significant bleeding or significant bleeding tendency within the previous 4 weeks were screened;

14. Complicated with other malignant tumors within 3 years before the first administration;

15. Poorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);

16. Diabetic patients with poor glycemic control;

17. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of GNC-077;

18. Who had participated in a clinical trial of an unmarketed drug within 4 weeks before the trial dose;

19. Had received a live vaccine within 4 weeks before the trial dose;

20. Other circumstances that the investigator deemed inappropriate for participation in the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Lin Shen

Role: primary

Other Identifiers

GNC-077-103

Identifier Type: -

Identifier Source: org_study_id